RecruitingPhase 2NCT06119789

Precision Cancer Therapy in Rare Cancers

The MATRIX Clinical Studies of Precision Cancer Therapy for Rare Cancers


Sponsor

Oslo University Hospital

Enrollment

96 participants

Start Date

Mar 20, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Some rare cancers are hard-to-treat and patients have a poor prognosis. It is known that some of these patients have targetable molecular alterations, and some benefit from targeted drugs. However in many cases these drugs are not approved for the rare cancers. In this study the aim is to do advanced molecular diagnostics to identify possible targets for therapy, and to treat accordingly.


Eligibility

Min Age: 16 YearsMax Age: 99 Years

Inclusion Criteria3

  • ECOG 0-2,
  • identified biomarker,
  • reasonable biochemistry

Exclusion Criteria2

  • ECOG 3-5
  • serious other diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGImatinib

imatinib treatment based on molecular alterations

DRUGTrametinib

According to biomarkers

DRUGDabrafenib

According to biomarkers


Locations(1)

Oslo University Hospital

Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06119789


Related Trials